PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 9/00, 31/48

A1

(11) International Publication Number: WO 98/52542

(43) International Publication Date: 26 November 1998 (26.11.98)

(21) International Application Number: PCT/US98/10155

(22) International Filing Date: 18 May 1998 (18.05.98)

(30) Priority Data:

9710496.2	21 May 1997 (21.05.97)	GB
9803990.2	25 February 1998 (25.02.98)	GB

(71) Applicant *(for all designated States except US)*: MINNESOTA MINING AND MANUFACTURING COMPANY [US/US]; 3M Center, P.O. Box 33427, Saint Paul, MN 55133–3427 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: OLIVER, Martin, J. [GB/GB]; 37 St. Leonards Road, Clarendon Park, Leicester LE2 1WS (GB). FATANIA, Kanu, M. [GB/GB]; 32 Leopold Street, Loughborough, Leicestershire LE11 5DL (GB). SCOTT, John, S. [GB/GB]; 12 Waver Close, Loughborough, Leicestershire LE11 2LG (GB). MULLER, Helgert [DE/DE]; Lerchental 1A, D–78315 Radolfzell (DE).

(74) Agents: RINGSRED, Ted, K. et al.; Minnesota Mining and Manufacturing Company, Office of Intellectual Property Counsel, P.O. Box 33427, Saint Paul, MN 55133–3427 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: MEDICINAL AEROSOL PRODUCTS

(57) Abstract

A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including the anti–inflammatory drug ciclesonide, hydrofluorocarbon propellants such as HFC 134a and/or 227, and ethanol in an amount sufficient to solubilize the ciclesonide (and various optional ingredients, such as surfactant). The formulations exhibit very desirable physical and chemical stability, as well as excellent delivery characteristics.